Filing Details

Accession Number:
0001209191-23-056071
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-11-20 16:31:38
Reporting Period:
2023-11-16
Accepted Time:
2023-11-20 16:31:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1850906 Singular Genomics Systems Inc. OMIC Laboratory Analytical Instruments (3826) 812948451
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1859701 Andrew Spaventa 3010 Science Park Road
San Diego CA 92121
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-11-16 43,468 $0.41 3,986,206 No 4 P Indirect By The Andrew K. Spaventa Living Trust dated April 9, 2014
Common Stock Acquisiton 2023-11-17 75,000 $0.42 4,061,206 No 4 P Indirect By The Andrew K. Spaventa Living Trust dated April 9, 2014
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By The Andrew K. Spaventa Living Trust dated April 9, 2014
No 4 P Indirect By The Andrew K. Spaventa Living Trust dated April 9, 2014
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 9,766 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.3770 to $0.4200, inclusive. The reporting person undertakes to provide to Singular Genomics Systems, Inc., any security holder of Singular Genomics Systems, Inc., or the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.4200 to $0.4456, inclusive. The reporting person undertakes to provide to Singular Genomics Systems, Inc., any security holder of Singular Genomics Systems, Inc., or the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.